Post by Kymera Therapeutics

Today, we announced that the first participant has been dosed in the Phase 1 clinical trial of KT-485, our oral, potent and selective IRAK4 degrader being advanced by Sanofi under our collaboration. This milestone marks an important step forward for KT-485 and its potential to offer a novel oral approach to addressing a key pathway involved in several immuno-inflammatory conditions. Read the full press release: https://bit.ly/4dYogPj #RevolutionizingImmunology